Hot or Not, Stock Market Edition: 11/10/2026

Happy Monday. Here’s what the Zen Ratings are checking in and checking out today:

• Hot: Hospital operator Ardent Health (ARDT) is looking good after a Q3 beat; endocrinology specialist Xeris Biopharma (XERS) just hit a fresh 52-week high on raised guidance
• Not: Mortgage lender UWM Holdings (UWMC) has fallen 75% from its high; aggregates giant Martin Marietta (MLM) is ranked at the bottom of its industry

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

The ONLY AI opportunity you should be looking at

This is the ONLY AI wealth-building opportunity you should be watching right now.

No. It's not about Nvidia, Tesla, or Meta...

It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.

This new opportunity will change the market and make investors a lot of money.

That's why it has received a $500 billion commitment from President Trump himself...

Learn more about this little-known company here >>>

🔥 HOT: Hospital operator Ardent Health (ARDT) just gave investors a strong quarter and a fresh vote of confidence from Wall Street. Earnings and revenue beat estimates, RBC raised its price target, and shares jumped nearly 10%. Ardent is also using AI to streamline care across more than a million patient encounters, which matters in a business where small efficiency gains can move margins.

Our market-beating quant model agrees with the bull case. ARDT has a Zen Rating of A, a Strong Buy recommendation. The Component Grades show why the move has substance: Momentum, Sentiment, and Safety all earn A grades, while Value and Growth receive B grades. That means the stock trend is strong, analyst confidence is improving, and the business is delivering with relatively predictable results. Bottom line: Ardent has fresh earnings momentum, improving efficiency, and broad support behind the rally.

🥶 NOT: Mortgage lender UWM Holdings (UWMC) is still fighting a housing market that refuses to cooperate. Revenue is expected to shrink, cash flow is deeply negative, leverage is extreme, and the stock has lost most of its value since going public. The nearly 20% dividend yield may grab attention, but for investors that payout looks less attractive when the core business is still under pressure.

UWMC has a Zen Rating of F, a Strong Sell recommendation. The Component Grades show where the biggest weakness sits: Momentum earns an F, while Sentiment and Artificial Intelligence receive D grades. That says the stock trend is poor and confidence remains weak even if parts of the underlying business are holding up. Bottom line: UWM may benefit if housing improves, but right now investors are being paid a huge yield to wait on a recovery that has not arrived.

🔥 HOT: Endocrinology biotech Xeris Biopharma (XERS) is flexing a near-perfect catalyst stack. Earnings and revenue beat estimates, management raised full-year sales guidance, and two analysts immediately lifted their price targets. Shares jumped more than 15%, while the company moves closer to breakeven and advances a Phase 3 thyroid drug that could add another growth engine.

And yes, our quant model likes the stock. XERS has a Zen Rating of A, a Strong Buy recommendation. The underlying Component Grades show why the excitement is broader than one good quarter: Growth and Momentum both earn A grades, while Sentiment, Financials, and Artificial Intelligence receive B grades. That points to accelerating business performance, a powerful stock trend, and improving confidence all at once. Bottom line: raised guidance, a strengthening financial profile, and a late-stage pipeline catalyst make Xeris one of the more compelling growth stories here.

Note: Looking for more timely stocks? Get these while they’re hot.

🥶 NOT: Building materials giant Martin Marietta (MLM) just posted record results, but investors have to look past the quarter. The company raised revenue guidance and completed a massive acquisition, yet earnings are expected to fall sharply next year while debt has climbed. For investors, that creates a classic tension: a strong backward-looking report against a much weaker forward setup.

MLM has a Zen Rating of F, a Strong Sell recommendation. The Component Grades help explain why the model is skeptical despite the record quarter: Value, Momentum, and Sentiment all earn D grades, while the rest sit at C. That suggests the stock is not especially attractive on price, the trend has weakened, and expectations are moving in the wrong direction. Bottom line: Martin Marietta may have just delivered a great quarter, but the next year matters more, and right now the forecast points the wrong way.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.